Mandate

Nordstjernan invests in Mama Mia

December 20, 2017 M&A

Vinge has advised Nordstjernan in conjunction with the acquisition of the majority of shares in Barnmorskegruppen MAMA MIA Aktiebolag (”Mama Mia”), as a supplementary acquisition to Lideta Hälsovård.

Mama Mia conducts prenatal and childcare services at seven units in Stockholm and Malmö, as well as primary care at two units in Stockholm under the trademark, To Care. The company has grown quickly over the last few years and during the last financial year its turnover was approximately MSEK 200 with approximately 170 employees.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Samra Baytar, Josephine Andersson, Martin Boström, Frida Ställborn and Mikaela Lang.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026